NCT02134834View on ClinicalTrials.gov

A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy VolunteersBacterial Infections
Interventions
DRUG

OP0595

Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

DRUG

Placebo

Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation

Trial Locations (1)

Unknown

Perth

Sponsors
All Listed Sponsors
lead

Meiji Seika Pharma Co., Ltd.

INDUSTRY

NCT02134834 - A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595 | Biotech Hunter | Biotech Hunter